Overall, the present NMA highlights vaginal progesterone with the addition of subcutaneous GnRH agonist as a single (Day 3 post‐FET) or double (and on Day 6 post FET) dose, which may improve clinical pregnancy outcomes, especially in medicated frozen cycles whilst reducing miscarriage events, albeit the latter not reaching statistical significance. The gene discussed is GNRH1; the disease is spontaneous abortion.